Cardiovascular Outcomes Data Transparency Vexes FDA, Sponsors
Executive Summary
FDA plans a public hearing Aug. 11 on confidentiality of interim results in cardiovascular outcomes safety trials, an issue that apparently has led to regulatory delays for Orexigen’s obesity treatment Contrave and Sanofi’s antidiabetic agent lixisenatide.
You may also be interested in...
Orexigen’s Big Plans On Hold As FDA Hashes Out Post-Marketing Requirements
Weight loss drug Contrave delayed by three months while sponsor and agency discuss how to handle data transparency for ongoing cardiovascular outcomes trial.
Orexigen Hopes FDA Sees The LIGHT On Contrave NDA
Contrave could be approved by FDA in 2014, making it the third obesity therapeutic to reach the market in the last two years. An interim analysis of the CV outcomes study LIGHT demonstrates a favorable risk-benefit profile, management said.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.